Elias Zerhouni - Danaher Independent Director
| DHR Stock | USD 272.09 2.29 0.83% |
Director
Dr. Elias A. Zerhouni, M.D. is Independent Director of the Company. Dr. Zerhouni has served as President, Global Research Development, for Sanofi S.A., a global pharmaceutical company, since January 2011. From 2008 until 2011, he provided advisory and consulting services to various nonprofit and other organizations as Chairman and President of Zerhouni Holdings. From 2002 to 2008, Dr. Zerhouni served as director of the National Institutes of Health, and from 1996 to 2002, he served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the Johns Hopkins School of Medicine. Dr. Zerhouni, a physician, scientist and worldrenowned leader in radiology research, is widely viewed as one of the leading authorities in the United States on emerging trends and issues in medicine and medical care. These insights, as well as his deep, technical knowledge of the research and clinical applications of medical technologies, are of considerable importance given Danahers strategic focus in the medical technologies markets since 2009.
| Age | 69 |
| Tenure | 15 years |
| Address | 2200 Pennsylvania Avenue, North West, Washington, DC, United States, 20037-1701 |
| Phone | 202 828 0850 |
| Web | https://www.danaher.com |
Elias Zerhouni Latest Insider Activity
Tracking and analyzing the buying and selling activities of Elias Zerhouni against Danaher stock is an integral part of due diligence when investing in Danaher. Elias Zerhouni insider activity provides valuable insight into whether Danaher is net buyers or sellers over its current business cycle. Note, Danaher insiders must abide by specific rules, including filing SEC forms every time they buy or sell Danaher'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Elias Zerhouni over six months ago Acquisition by Elias Zerhouni of 216 shares of Danaher subject to Rule 16b-3 |
Danaher Management Efficiency
The company has Return on Asset of 0.0398 % which means that on every $100 spent on assets, it made $0.0398 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0798 %, implying that it generated $0.0798 on every 100 dollars invested. Danaher's management efficiency ratios could be used to measure how well Danaher manages its routine affairs as well as how well it operates its assets and liabilities. As of 10/22/2024, Return On Equity is likely to grow to 0.15, while Return On Tangible Assets are likely to drop 0.14. At this time, Danaher's Debt To Assets are relatively stable compared to the past year. As of 10/22/2024, Fixed Asset Turnover is likely to grow to 5.76, while Return On Tangible Assets are likely to drop 0.14.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Virginia Wilson | Charles River Laboratories | 66 | |
| George Scangos | Agilent Technologies | 72 | |
| Gary Hendrickson | Waters | 64 | |
| James Mullen | Thermo Fisher Scientific | 62 | |
| Elaine Ullian | Thermo Fisher Scientific | 70 | |
| Laurie Glimcher | Waters | 66 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| Linda Baddour | Waters | 62 | |
| Tadataka Yamada | Agilent Technologies | 74 | |
| Richard Wallman | Charles River Laboratories | 69 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| Paul Clark | Agilent Technologies | 72 | |
| Christopher Kuebler | Waters | 66 | |
| George Massaro | Charles River Laboratories | 73 | |
| Daniel Podolsky | Agilent Technologies | 67 | |
| Martin Mackay | Charles River Laboratories | 65 | |
| Edward Conard | Waters | 63 | |
| Sue Rataj | Agilent Technologies | 63 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Michael Kelly | Mettler Toledo International | 64 | |
| Thomas Salice | Waters | 61 | |
Management Performance
| Return On Equity | 0.0798 | ||||
| Return On Asset | 0.0398 |
Danaher Leadership Team
Elected by the shareholders, the Danaher's board of directors comprises two types of representatives: Danaher inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Danaher. The board's role is to monitor Danaher's management team and ensure that shareholders' interests are well served. Danaher's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Danaher's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rainer Blair, President, Chief Executive Officer, Director | ||
| Angela Lalor, Senior Vice President - Human Resources | ||
| Pardis Sabeti, Independent Director | ||
| A Sanders, Independent Director | ||
| William King, Senior Vice President - Strategic Development | ||
| Matthew McGrew, Chief Financial Officer, Executive Vice President | ||
| Thomas Joyce, CEO and President Director and Member of Fin. Committee | ||
| Mitchell Rales, Chairman of the Executive Committee, Director | ||
| JoseCarlos GutierrezRamos, Senior Vice President Chief Scientific Officer | ||
| John Schwieters, Independent Director | ||
| Linda Filler, Lead Independent Director | ||
| Teri ListStoll, Independent Director | ||
| Daniel Raskas, Senior Vice President - Corporate Development | ||
| Daniel Comas, Executive Vice President | ||
| Elias Zerhouni, Independent Director | ||
| Brian Ellis, Senior Vice President, Chief Compliance Officer, General Counsel | ||
| Daniel JD, Senior Development | ||
| Raymond Stevens, Independent Director | ||
| Jessica Mega, Independent Director | ||
| Steven Rales, Chairman of the Board | ||
| John Bedford, Vice Relations | ||
| Alan Spoon, Independent Director | ||
| Robert Lutz, Senior Vice President Chief Accounting Officer | ||
| Walter Lohr, Independent Director | ||
| Christopher Bouda, Chief Accounting Officer, Vice President | ||
| Georgeann Couchara, Senior Vice President - Human Resources | ||
| Joakim Weidemanis, Executive Vice President | ||
| Jennifer Honeycutt, Executive Vice President |
Danaher Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Danaher a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0798 | ||||
| Return On Asset | 0.0398 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 212.35 B | ||||
| Shares Outstanding | 722.21 M | ||||
| Shares Owned By Insiders | 10.99 % | ||||
| Shares Owned By Institutions | 82.69 % | ||||
| Number Of Shares Shorted | 5.64 M | ||||
| Price To Earning | 29.97 X |
Pair Trading with Danaher
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Danaher position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Danaher will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Danaher could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Danaher when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Danaher - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Danaher to buy it.
The correlation of Danaher is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Danaher moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Danaher moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Danaher can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Danaher Stock Analysis
When running Danaher's price analysis, check to measure Danaher's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Danaher is operating at the current time. Most of Danaher's value examination focuses on studying past and present price action to predict the probability of Danaher's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Danaher's price. Additionally, you may evaluate how the addition of Danaher to your portfolios can decrease your overall portfolio volatility.